Interleukin-7 and interleukin-15 for cancer

Paul Zarogoulidis, Sofia Lampaki, Lonny Yarmus, Ioannis Kioumis, Georgia Pitsiou, Nikolaos Katsikogiannis, Wolfgang Hohenforst-Schmidt, Qiang Li, Haidong Huang, Antonios Sakkas, John Organtzis, Leonidas Sakkas, Ioannis Mpoukovinas, Kosmas Tsakiridis, George Lazaridis, Konstantinos Syrigos, Konstantinos Zarogoulidis

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Interleukin 7 and 15 are considered powerful pro-inflammatory cytokines, they have the ability to destabilize chromosomes and induce tumorigenesis. Additionally, they can control malignancy proliferation by influencing the tumor microenvironment and immune system. Immunotherapy has been proposed as a treatment modality for malignancy for over a decade; the exact mechanisms of action and pathways are still under investigation. Interleukin 7 and 15 have been extensively investigated in hematological malignancies since their mode of action influences the stimulation of the immune system in a more direct way than other malignancies such as lung, melanoma, and breast, renal and colorectal cancer.

Original languageEnglish (US)
Pages (from-to)765-773
Number of pages9
JournalJournal of Cancer
Issue number9
StatePublished - 2014


  • Cancer
  • IL-15
  • IL-7
  • Imunomodulation

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Interleukin-7 and interleukin-15 for cancer'. Together they form a unique fingerprint.

Cite this